RATIONALE: Dupilumab, a monoclonal antibody against IL-4 receptor alpha (IL-4Ra) that blocks signaling of IL-4 and IL-13 cytokines, is approved by FDA for treatment of severe atopic dermatitis. TH2 cytokines such as IL-4 and IL-13 are involved in the pathogenesis of atopic dermatitis and other allergic disorders. More recently, group 2 innate lymphoid cells (ILC2s) have been described to play a role in allergic disorders including atopic dermatitis. ILC2s produce TH2 cytokines including IL-4 and IL-13. We sought to identify the effect of dupilumab, which blocks IL-4 and IL-13 signaling, on ILC2s. METHODS: Five patients with severe atopic dermatitis treated with dupilumab and three healthy controls were recruited from Albany Medical College Allergy Clinic. Peripheral blood mononuclear cells were separated from whole blood using Ficoll method. Flow cytometry was used to identify ILC2s. RESULTS: In a subset of patients with severe atopic dermatitis on dupilumab, results showed there was reduced frequency of ILC2 compared to healthy controls. CONCLUSIONS: Inhibition of IL-4 and IL-13 signaling through IL-4Ra may lead to decrease frequency of ILC2. More studies are needed to understand the exact mechanism by which IL-4 receptor signaling pathway affects ILC2s. Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, M alaga, Spain, 2 Allergy Unit, Regional University Hospital of Malaga-IBIMA-UMA, M alaga, Spain, 3 BIONAND -Andalusian Centre for Nanomedicine and Biotechnology, M alaga, Spain. RATIONALE: Nowadays, selective reactions to clavulanic acid (CLV) account for 30% of all reactions to the combination of amoxicillin-CLV. However, the sensitivity of in vitro diagnostic tests is not optimal. The identification of the precise antigenic determinants (AD) that are recognized by the immune system could improve the diagnostic methods. Therefore, our aim was to evaluate the recognition of different synthetic determinants of CLV by dendritic cells (DCs). METHODS: Based on different CLV degradation pathways, 2 AD were proposed and 3 structures were synthesized from each AD: AD-I (CLV1-3) and AD-II (CLV4-6). Peripheral blood mononuclear cells were collected from 10 patients with selective reactions to CLV and 10 controls. Monocyte-derived DCs were cultured with CLV and with the different synthetic structures. CCR7, CD40, CD80, CD83 and CD86 expression were analyzed by flow cytometry. Results were represented as maturation index (MI). RESULTS: DCs from patients cultured with CLV did not show significant modification in the evaluated markers compared to controls. Higher MI of CCR7, CD40, CD80 and CD83 were found in DCs cultured with CLV2, CLV3 and CLV6 compared to controls. However, the inclusion of CLV1, CLV4 and CLV5 did not improve the analysis. No difference was shown in the expression of CD86 in any case. CONCLUSIONS: Better recognition by DCs of CLV2, CLV3 and CLV6 is obtained compared with CLV itself. The inclusion of these analogs from both AD could improve the sensitivity of in vitro assays and become useful in the diagnosis of these reactions. Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan. RATIONALE: Intravenous immunoglobulin (IVIG) treatment effectively suppresses coronary artery inflammation and reduces the incidence of coronary aneurysms in most patients with Kawasaki disease (KD). However, some patients develop coronary aneurysms, presumably due to IL-1b overexpression. We previously reported that IVIG effectively inhibited TNF-a-induced, but never IL-1b-induced, IL-6 expression by cultured human coronary artery endothelial cells (HCAECs). The aim of this study was to clarify the role of C/EBPd, a transcription factor for IL-6, in HCAECs in IVIG-refractory KD. METHODS: HCAECs were stimulated with TNF-a or IL-1b in the presence and absence of 10 mg/ml IVIG for 48 hours. IL-6 mRNA and protein were measured by qPCR and ELISA, respectively. Expression and DNA-binding activity of C/EBPd were analyzed by immunoblotting and EMSA assay, respectively. RESULTS: Consistent with our previous study, IVIG completely inhibited TNF-a-induced expression and activity of C/EBPd in HCAECs. In sharp contrast, IVIG hardly affected IL-1b-induced activation of C/EBPd in HCAECs. CONCLUSIONS: C/EBPd may play a crucial role in the anti-inflammatory mechanisms of IVIG and could be a novel therapeutic target, especially for IVIG-resistant KD.
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